Company intelligence / Profile preview
AbelZeta
Rockville, Maryland, United Statesabelzeta.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AbelZeta has demonstrated high response rates and durable remissions in relapsed/refractory B-cell lymphoma with its lead CAR-T program C-CAR039 (dual CD19/CD20), and obtained FDA RMAT designation for C-CAR168 in refractory SLE/LN. Earlier results support a best-in-class potential, with 4-year overall response and complete response rates of 91.5% and 85.1% for C-CAR039, and collaborations indicate broad indicator exploration.
- Therapeutic areas
- OncologyImmunology
- Modalities
- CAR-T cell therapyCell therapyTumor-infiltrating lymphocyte therapy
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
03
Partnerships
Janssen Biotech (Johnson & Johnson) – global license and collaboration for two autologous CD20-directed CAR-Ts
Beyond the preview
Go deeper on AbelZeta.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AbelZeta.